Your browser doesn't support javascript.
loading
Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome.
Norton, Jeffrey A; Krampitz, Geoffrey W; Poultsides, George A; Visser, Brendan C; Fraker, Douglas L; Alexander, H Richard; Jensen, Robert T.
Afiliação
  • Norton JA; Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • Krampitz GW; Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • Poultsides GA; Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • Visser BC; Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • Fraker DL; University of Pennsylvania, School of Medicine, Philadelphia, PA.
  • Alexander HR; University of Maryland, School of Medicine, Baltimore, MD.
  • Jensen RT; Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Ann Surg ; 267(4): 782-788, 2018 04.
Article em En | MEDLINE | ID: mdl-29517561
ABSTRACT

OBJECTIVE:

To determine the role of reoperation in patients with persistent or recurrent Zollinger-Ellison Syndrome (ZES).

BACKGROUND:

Approximately, 0% to 60% of ZES patients are disease-free (DF) after an initial operation, but the tumor may recur.

METHODS:

A prospective database was queried.

RESULTS:

A total of 223 patients had an initial operation for possible cure of ZES and then were subsequently evaluated serially with cross sectional imaging-computed tomography, magnetic resonance imaging, ultrasound, more recently octreoscan-and functional studies for ZES activity. The mean age at first surgery was 49 years and with an 11-year mean follow-up 52 patients (23%) underwent reoperation when ZES recurred with imageable disease. Results in this group are analyzed in the current report. Reoperation occurred on a mean of 6 years after the initial surgery with a mean number of reoperations of 1 (range 1-5). After reoperation 18/52 patients were initially DF (35%); and after a mean follow-up of 8 years, 13/52 remained DF (25%). During follow-up, 9/52 reoperated patients (17%) died, of whom 7 patients died a disease-related death (13%). The overall survival from first surgery was 84% at 20 years and 68% at 30 years. Multiple endocrine neoplasia type 1 status did not affect survival, but DF interval and liver metastases did.

CONCLUSIONS:

These results demonstrate that a significant proportion of patients with ZES will develop resectable persistent or recurrent disease after an initial operation. These patients generally have prolonged survival after reoperation and 25% can be cured with repeat surgery, suggesting all ZES patients postresection should have systematic imaging, and if tumor recurs, advise repeat operation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reoperação / Síndrome de Zollinger-Ellison Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reoperação / Síndrome de Zollinger-Ellison Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Ano de publicação: 2018 Tipo de documento: Article